Shai Mulinari
21 – 30 of 101
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Authors’ reply to Fell
- Contribution to journal › Letter
-
Mark
Unethical pharmaceutical marketing: a common problem requiring collective responsibility
- Contribution to journal › Article
-
Mark
International comparison of pharmaceutical industry payment disclosures in the UK and Japan: implications for self-regulation, public regulation, and transparency
- Contribution to journal › Article
-
Mark
Short-circuiting biology: Digital phenotypes, digital biomarkers, and shifting gazes in psychiatry
(2023) In Big Data and Society
- Contribution to journal › Article
- 2022
-
Mark
Capitalizing on transparency: commercial surveillance and pharmaceutical marketing after the Physician Sunshine Act
- Contribution to journal › Article
-
Mark
Disclosure of Pharmaceutical Industry Funding of Patient Organisations in Nordic Countries: Can Industry Self-Regulation Deliver on its Transparency Promise?
- Contribution to journal › Article
-
Mark
The making of a Swedish strategy : How organizational culture shaped the Public Health Agency's pandemic response
- Contribution to journal › Article
-
Mark
A “patient-industry complex”? Investigating the financial dependency of UK patient organisations on drug company funding
- Contribution to journal › Article
-
Mark
Tip of the iceberg? Country- and company-level analysis of drug company payments for research and development in Europe
- Contribution to journal › Article
-
Mark
Content and strength of conflict of interest policies at Scandinavian Medical Schools: a cross sectional study
- Contribution to journal › Article
